Enhertu (fam-trastuzumab deruxtecan) has a half-life of approximately 5.7 to 5.8 days, meaning measurable drug levels drop by half roughly every six days. Based on the standard pharmacology rule that it takes about five half-lives to clear a drug from your body, Enhertu’s active components are largely eliminated within four to five weeks after your last infusion. However, the official safety recommendations extend much further: women are advised to use contraception for at least 7 months after the final dose, which reflects a wider margin of caution beyond simple drug clearance.
How the Half-Life Works
Enhertu is an antibody-drug conjugate, which means it has two functional parts: a large antibody that targets HER2 on cancer cells and a small chemotherapy payload called DXd that kills those cells from the inside. Each component leaves your body on a slightly different timeline, but the intact conjugate has a terminal half-life near 5.8 days.
After one half-life (about 6 days), half the drug is gone. After two half-lives (about 12 days), 75% is gone. By five half-lives, roughly 29 days, about 97% of the drug has been cleared. This is the standard threshold pharmacologists use to consider a medication essentially out of your system. In practice, most patients can expect drug levels to be negligible about a month after their last infusion.
How Your Body Breaks Down Enhertu
The antibody portion of Enhertu is broken down the same way your body recycles its own antibodies: it gets dismantled into small protein fragments and amino acids through normal metabolic processes. The chemotherapy payload, DXd, is processed primarily by a liver enzyme called CYP3A4. In preclinical studies, the major route of excretion for DXd was through stool, and the only detectable form in both urine and stool was unchanged DXd, meaning the payload passes through largely intact rather than being converted into other byproducts.
This matters if you’re taking other medications that affect that same liver enzyme. Drugs that strongly inhibit or boost CYP3A4 activity could theoretically slow down or speed up clearance of the chemotherapy component, though dose adjustments are not routinely made for this reason.
Reaching Steady State During Treatment
Enhertu is given as an intravenous infusion every three weeks. Because each dose hasn’t fully cleared before the next one arrives, the drug accumulates in your system over multiple cycles. Population modeling suggests that true steady-state levels, where the amount entering and leaving your body reaches equilibrium, are achieved around 10 dosing cycles. That translates to roughly 30 weeks of treatment before drug levels fully plateau. This gradual buildup is normal for antibody-based therapies and is factored into the dosing schedule.
Why Safety Windows Extend Beyond Clearance
Even though the drug itself is functionally cleared within about a month, the recommended precautionary timelines are significantly longer. Women of reproductive age are advised to use effective contraception during treatment and for at least 7 months after the last dose. Male patients with female partners of reproductive age should use contraception for at least 4 months after their final dose. Women are also advised not to breastfeed during treatment and for 7 months following the last infusion.
These windows are not based solely on how long the drug circulates in your blood. They account for the time it takes for the chemotherapy component to fully clear from all tissues, the potential for lingering effects on egg and sperm development, and built-in safety margins to protect a developing fetus or nursing infant. Egg maturation, for example, takes several months, so the contraception window covers the period during which eggs exposed to the drug might still be released.
Factors That May Affect Your Timeline
Your individual clearance rate can vary based on several factors. Body weight influences how the drug distributes through your system, and liver function matters because the chemotherapy payload depends on liver enzymes for processing. Patients with significant liver impairment may clear DXd more slowly, though mild to moderate impairment does not typically require dose changes.
How long you were on treatment also plays a role. Someone who received Enhertu for many months will have higher tissue saturation than someone who had only a few cycles. While blood levels still follow the same half-life curve after the last dose, the subjective experience of side effects fading may take longer in patients who were on treatment for an extended period. Most lingering side effects like fatigue and nausea improve progressively over the weeks following your final infusion, roughly tracking the drug’s clearance from your body.